Travere Therapeutics to Report First Quarter 2022 Financial Results
Travere Therapeutics (NASDAQ: TVTX) plans to release its first quarter 2022 financial results on May 5, 2022, following the U.S. market close. A conference call and webcast to discuss these results and provide a business update is scheduled for 4:30 p.m. ET.
Investors can join the call using the provided dial-in numbers, and a replay will be accessible from 7:30 p.m. ET on May 5 until 7:30 p.m. ET on May 12.
- Scheduled financial report on May 5, 2022, indicating ongoing business activity.
- Conference call to provide investors with insights into quarterly performance.
- None.
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Conference Call Information
| Date: | Thursday, May 5, 2022 |
| Time: | 4:30 p.m. ET |
| Dial-in numbers: | +1 (800) 289-0720 (U.S.) or +1 (313) 209-5140 (International) |
| Confirmation code: | 7273768 |
| Live webcast: | Travere.com in the “Events & Presentations” section of the “Investors” page |
A replay of the call will be available from 7:30 p.m. ET, May 5, 2022, to 7:30 p.m. ET, May 12, 2022. The replay number is +1 (888) 203-1112 (U.S.) or +1 (719) 457-0820 (International), confirmation code 7273768.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com
Contact:
Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate Communications
888-969-7879
IR@travere.com
FAQ
When will Travere Therapeutics report its first quarter 2022 financial results?
What time is the conference call for Travere Therapeutics' financial results?
How can I access the replay of Travere Therapeutics' conference call?
